Pharmabiz

US FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx, a companion diagnostic indicated to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

US FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx, a companion diagnostic indicated to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma Santa Clara, California ...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic ...
news.bloomberglaw

BDT & MSD Near $1 Billion Deal That Includes Disney Four Seasons

BDT & MSD Partners is close to acquiring a Four Seasons resort in Orlando from Host Hotels & Resorts Inc. in a rare deal for a hotel located on a Walt Disney Co. property. The investment firm would ...
Frontiers

Association of gut microbiota and short-chain fatty acids with pre-diabetes and diabetes following gestational diabetes

Department of Endocrinology, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China Background: Emerging evidence demonstrates correlations among the ...